• Medientyp: E-Artikel
  • Titel: A case report of systemic mastocytosis associated with multiple hematologic non–mast cell lineage diseases
  • Beteiligte: Grifoni, Federica Irene; Sciumè, Mariarita; Pravettoni, Valerio; Ulivieri, Fabio Massimo; Muratori, Simona; Fracchiolla, Nicola Stefano; Tagliaferri, Elena; Gianelli, Umberto; Migliorini, Anna Chiara; Cro, Lilla; Pacilli, Annalisa; Mannelli, Francesco; Baldini, Luca
  • Erschienen: Wiley, 2019
  • Erschienen in: Hematological Oncology
  • Umfang: 205-211
  • Sprache: Englisch
  • DOI: 10.1002/hon.2605
  • ISSN: 1099-1069; 0278-0232
  • Schlagwörter: Cancer Research ; Oncology ; Hematology ; General Medicine
  • Zusammenfassung: <jats:title>Abstract</jats:title><jats:p>Systemic mastocytosis (SM) is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent SM, aggressive SM, and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: SM with an associated hematological neoplasm, which is characterized by the presence of a concurrent neoplasm, more commonly, a chronic myelomonocytic leukemia. While <jats:italic>KIT</jats:italic> D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied. Treatment of SM might not be simple, but now more specific therapies tailored toward prognostic subgroups of patients have been developed. Here, we report a detailed description of clinical management and biological features of a systemic mastocytocis case associated with multiple hematologic non–mast cell lineage diseases.</jats:p>
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>Systemic mastocytosis (SM) is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent SM, aggressive SM, and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: SM with an associated hematological neoplasm, which is characterized by the presence of a concurrent neoplasm, more commonly, a chronic myelomonocytic leukemia. While <jats:italic>KIT</jats:italic> D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied. Treatment of SM might not be simple, but now more specific therapies tailored toward prognostic subgroups of patients have been developed. Here, we report a detailed description of clinical management and biological features of a systemic mastocytocis case associated with multiple hematologic non–mast cell lineage diseases.</jats:p>
  • Anmerkungen: